Antibody and cellular responses to HIV vaccine regimens with DNA plasmid as compared with ALVAC priming: An analysis of two randomized controlled trials
Moodie Z., Walsh S.R., Laher F., Maganga L., Herce M.E., Naidoo S., Hosseinipour M.C., Innes C., Bekker L.G., Grunenberg N., Mann P., Yu C., deCamp A.C., Miner M.D., Yates N.L., Heptinstall J., Mkhize N.N., Dintwe O., Frahm N., Cohen KW., Allen M., Hutter J., Wagner R., Pantaleo G., McElrath M.J., Tomaras G.D., Morris L., Montefiori D.C., Andersen-Nissen E., Gray G.E., Gilbert P.B., Kublin J.G.; NIAID HVTN 100 and HVTN 111 trial teams.
May 22, 2020 | Publications